YC Biotech and Friendly Taipei Community Health Care Group successfully held a signing event at Brown Cafe, announcing their partnership to promote EG BioMed’s DNA Methylation Cancer Biomarker Test. This collaboration marks a significant advancement in breast cancer detection methods, with the technology standing out for its simplicity, speed, and accuracy, offering a more comfortable testing experience for the patients.
The event concluded successfully, followed by an in-depth discussion on the specificity and sensitivity of DNA methylation testing compared to traditional imaging methods. This discussion is considered crucial for further understanding the clinical applications and advantages of this technology.
YC Biotech also announced that the DNA Methylation Cancer Biomarker Test has been formally submitted to the U.S. Food and Drug Administration (FDA) for certification, with approval expected within a month. This progress will enable the technology to gain broader recognition in the international market. Friendly Taipei Community Health Care Group expressed that this collaboration will enhance their ability to provide high-quality cancer testing services, bringing YC Biotech’s innovative testing technology to a larger group of patients and further elevating their healthcare service quality.